Publications
Here you can browse the complete list of publications for studies listed on CDAS.
| Title | PubMed | Authors | Journal | Year | Studies |
|---|---|---|---|---|---|
| Prostate size, nocturia and the digital rectal examination: a cohort study of 30 500 men. | 27480499 | Stone BV, Shoag J, Halpern JA, Mittal S, Lewicki P, Golombos DM, Bedretdinova D, Chughtai B, Barbieri CE, Lee RK | BJU Int. | 2017 | PLCO |
| Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. | 27911486 | Pinsky PF, Prorok PC, Yu K, Kramer BS, Black A, Gohagan JK, Crawford ED, Grubb RL, Andriole GL | Cancer | 2017 | PLCO |
| Prostate Specific Antigen-Growth Curve Model to Predict High-Risk Prostate Cancer. | 27699819 | Shoaibi A, Rao GA, Cai B, Rawl J, Haddock KS, Hébert JR | Prostate | 2017 | PLCO |
| Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm. | 27569432 | Halpern JA, Shoag JE, Mittal S, Oromendia C, Ballman KV, Hershman DL, Wright JD, Shih YT, Nguyen PL, Hu JC | J. Urol. | 2017 | PLCO |
| Prediagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. | 27770434 | Trabert B, Eldridge RC, Pfeiffer RM, Shiels MS, Kemp TJ, Guillemette C, Hartge P, Sherman ME, Brinton LA, Black A, Chaturvedi AK, Hildesheim A, Berndt SI, Safaeian M, Pinto L, Wentzensen N | Int. J. Cancer | 2017 | PLCO |
| Prediagnostic Body Mass Index Trajectories in Relation to Prostate Cancer Incidence and Mortality in the PLCO Cancer Screening Trial. | 27754927 | Kelly SP, Graubard BI, Andreotti G, Younes N, Cleary SD, Cook MB | J. Natl. Cancer Inst. | 2017 | PLCO |
| Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer. | 28510291 | Wang Y, Freedman JA, Liu H, Moorman PG, Hyslop T, George DJ, Lee NH, Patierno SR, Wei Q | Int. J. Cancer | 2017 | PLCO |
| Circulating levels of obesity-related markers and risk of renal cell carcinoma in the PLCO cancer screening trial. | 28484923 | Liao LM, Hofmann JN, Cho E, Pollak MN, Chow WH, Purdue MP | Cancer Causes Control | 2017 | PLCO |
| Do Aspirin and Other NSAIDs Confer a Survival Benefit in Men Diagnosed with Prostate Cancer? A Pooled Analysis of NIH-AARP and PLCO Cohorts. | 28507039 | Zhou CK, Daugherty SE, Liao LM, Freedman ND, Abnet CC, Pfeiffer R, Cook MB | Cancer Prev Res (Phila) | 2017 | PLCO |
| Clinical validation of a blood-based classifier for diagnostic evaluation of asymptomatic individuals with pulmonary nodules. | 28694742 | Birse CE, Tomic JL, Pass HI, Rom WN, Lagier RJ | Clin Proteomics | 2017 | PLCO |
| Dietary intake of isoflavones and coumestrol and the risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. | 29114854 | Reger MK, Zollinger TW, Liu Z, Jones JF, Zhang J | Int. J. Cancer | 2017 | PLCO |
| Kinetics of the Human Papillomavirus Type 16 E6 Antibody Response Prior to Oropharyngeal Cancer. | 28376197 | Kreimer AR, Johansson M, Yanik EL, Katki HA, Check DP, Lang Kuhs KA, Willhauck-Fleckenstein M, Holzinger D, Hildesheim A, Pfeiffer R, Williams C, Freedman ND, Huang WY, Purdue MP, Michel A, Pawlita M, Brennan P, Waterboer T | J. Natl. Cancer Inst. | 2017 | PLCO |
| Prospective study of DNA methylation at chromosome 8q24 in peripheral blood and prostate cancer risk. | 28463958 | Barry KH, Moore LE, Sampson JN, Koutros S, Yan L, Meyer A, Reddy M, Oler AJ, Cook MB, Fraumeni JF, Yeager M, Amundadottir LT, Berndt SI | Br. J. Cancer | 2017 | PLCO |
| Evaluating the impact of varied compliance to lung cancer screening recommendations using a microsimulation model. | 28702814 | Han SS, Erdogan SA, Toumazis I, Leung A, Plevritis SK | Cancer Causes Control | 2017 | PLCO |
| Vasectomy and Risk of Prostate Cancer in a Screening Trial. | 28830873 | Shoag J, Savenkov O, Christos PJ, Mittal S, Halpern JA, Askin G, Shoag D, Golan R, Lee DJ, O'Malley P, Najari B, Eisner B, Hu JC, Scherr D, Schlegel P, Barbieri CE | Cancer Epidemiol. Biomarkers Prev. | 2017 | PLCO |
| Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials. | 28869989 | Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, de Carvalho TM, Hugosson J, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, Feuer EJ, de Koning HJ, Mariotto AB, Etzioni R | Ann. Intern. Med. | 2017 | PLCO |
| Early detection versus primary prevention in the PLCO flexible sigmoidoscopy screening trial: Which has the greatest impact on mortality? | 28976536 | Doroudi M, Schoen RE, Pinsky PF | Cancer | 2017 | PLCO |
| Use of Digital Rectal Examination as an Adjunct to Prostate Specific Antigen in the Detection of Clinically Significant Prostate Cancer. | 29061540 | Halpern JA, Oromendia C, Shoag JE, Mittal S, Cosiano MF, Ballman KV, Vickers AJ, Hu JC | J. Urol. | 2017 | PLCO |
| Outcomes from ovarian cancer screening in the PLCO trial: Histologic heterogeneity impacts detection, overdiagnosis and survival. | 29156299 | Temkin SM, Miller EA, Samimi G, Berg CD, Pinsky P, Minasian L | Eur. J. Cancer | 2017 | PLCO |
| The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials. | 29211316 | de Koning HJ, Gulati R, Moss SM, Hugosson J, Pinsky PF, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, de Carvalho TM, Feuer EJ, Tsodikov A, Mariotto AB, Heijnsdijk EAM, Etzioni R | Cancer | 2017 | PLCO |